Enzo Biochem Inc

Enzo Biochem — Investor Presentation (November 2015)

53 slides from Enzo Biochem's investor presentation, Nov 27, 2015

  1. Slide 1: Company Strategy and Overview

    November 2015 www.enzo.com Company Strategy and Overview

  2. Slide 2: Legal Disclaimer

    1 LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward - looking" statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such statements inc

  3. Slide 3: Table of Contents

    2 TABLE OF CONTENTS Page Summary of Company Strategy 4 Industry Dynamics : Growth and Challenges 7 Enzo’s Solution 17 Financial Overview 37 Appendices 44

  4. Slide 4: Molecular Diagnostics Strategy: From Challenges of Industry to Opportunities for Enzo

    November 2015 www.enzo.com Molecular Diagnostics Strategy… From Challenges of Industry to Opportunities for Enzo 3

  5. Slide 5: Summary of Company Strategy

    Summary of Company Strategy 4

  6. Slide 6: Enzo is an integrated diagnostics entity

    5 ENZO BIOCHEM ENZO BIOCHEM, INC . (“ENZO” OR THE “COMPANY”) IS AN INTEGRATED DIAGNOSTICS ENTITY THAT IS UNIQUELY STRUCTURED TO CAPITALIZE UPON ONGOING REIMBURSEMENT PRESSURES IN THE MOLECULAR DIAGNOSTICS MARKET Enzo’s vertically integrated structure positions it to benefit as a disruptor in molecul

  7. Slide 7: Synergistic value of the whole exceeds the sum of the parts

    Clinical Services Products Biotech 6 THE SYNERGISTIC VALUE OF THE WHOLE FAR EXCEEDS THE SUM - OF - THE - PARTS AND ALLOWS ENZO TO CONTINUE TO EXECUTE ON ITS STRATEGY Note: Block sizes are purely illustrative (1) Company estimates Benefits of Vertical Integration: Freedom to Operate, Cost Avoidance,

  8. Slide 8: Industry Dynamics: Growth and Challenges

    Industry Dynamics: Growth and Challenges 7

  9. Slide 9: Tremendous Demand for Molecular Diagnostics

    8 TREMENDOUS DEMAND FOR MOLECULAR DIAGNOSTICS $4.6 $4.9 $5.2 $5.6 $6.0 $6.5 $7.1 $3 $4 $4 $5 $5 $6 $6 $7 $7 $8 2012 2013 2014 2015 2016 2017 2018 ($ in billions) Molecular Diagnostics Opportunity In the span of 25 years, molecular diagnostics ( M Dx) have burgeoned from a practically non - existent

  10. Slide 10: Market Growth and Challenges, and Enzo's Opportunity

    9 MARKET GROWTH AND CHALLENGES… AND ENZO’S OPPORTUNITY Problem to Address: MDx Market Margins are Under Intense Pressure Demand for MDx is rapidly increasing Growing at 2x the rate of the overall diagnostic market (1) However, reimbursement for these tests is in long - term decline MDx margins withi

  11. Slide 11: Vertical Integration Eliminates Inefficiencies

    10 VERTICAL INTEGRATION ELIMINATES INEFFICIENCIES THE CURRENT FRAGMENTED MARKET STRUCTURE HAS MATERIAL INEFFICIENCIES Market needs to eliminate multiple layers of profit - taking in the development chain and commercialization of MDx Intellectual Property Biotech Innovation, Technology, and Test Plat

  12. Slide 12: The MDx Challenge: Vertical Integration

    11 THE MD x CHALLENGE : VERTICAL INTEGRATION BIOTECH, MD x, AND CLINICAL SERVICES COMPANIES IN TODAY’S MARKET ENVIRONMENT LACK THE NECESSARY OPERATING STRUCTURE AND RESOURCES TO EFFECTIVELY MEET THE CHALLENGES OF THE MD x MARKET From Concept to Commercialization Innovation & IP Technology Platform M

  13. Slide 13: Innovation and IP; Platform Development; Manufacturing; Validation

    12 INNOVATION AND IP Clinical labs have little or no IP Molecular diagnostic companies are dependent on third - party licensing and are capital - intensive SOPHISTICATED TECHNOLOGY PLATFORM DEVELOPMENT Clinical labs are dependent on manufacturers’ “closed systems” and other technologies that are roy

  14. Slide 14: Operational Efficiencies Have Already Virtually Maxed Out

    13 OPERATIONAL EFFICIENCIES HAVE ALREADY VIRTUALLY MAXED OUT Clinical labs have made substantial efforts to reduce costs and have focused their effort on labor expenses Market consolidation is largely complete Due to government mandated staffing levels, clinical labs are no longer able to continue t

  15. Slide 15: Impact of Impending Reimbursement Cuts on Diagnostic Companies

    (60.0%) (50.0%) (40.0%) (30.0%) (20.0%) (10.0%) 0.0% 10.0% 20.0% 30.0% 40.0% Genomic Health Inc. Veracyte, Inc. CareDx, Inc. 14 IMPACT OF IMPENDING REIMBURSEMENT CUTS ON DIAGNOSTIC COMPANIES “We expect several diagnostics stocks to trade off sharply following announced price cuts by the Centers for

  16. Slide 16: Unique Capabilities and Assets Required to Capitalize on Opportunity

    15 UNIQUE CAPABILITIES AND ASSETS ARE REQUIRED TO CAPITALIZE ON THIS DISRUPTIVE OPPORTUNITY Existing IP, technologies, and test platforms Ability to internally generate capital to finance innovation, technology, platforms, IP, product development, marketing, and accessibility Ability to address mult

  17. Slide 17: Enzo Products Structured to Disrupt the Market

    16 ENZO PRODUCTS STRUCTURED TO DISRUPT THE MARKET WITHOUT APPEARING DISRUPTIVE Building this Vertically Integrated, Self - Supporting, and Cash - Generating Business Requires a Focused, Diligent Strategy – ENZO HAS SUCH A STRATEGY We avoid the intermediate costs at each step... savings that we pass

  18. Slide 18: Enzo's Solution - Efficient, Self-Generated Development and Commercialization

    Enzo’s Solution - Efficient, Self - Generated Development and Commercialization 17

  19. Slide 19: The Fundamental Basis for Enzo's Solution

    18 THE FUNDAMENTAL BASIS FOR ENZO’S SOLUTION COST - EFFECTIVE HIGH - PERFORMANCE EASILY ADAPTABLE

  20. Slide 20: Economic Benefits of Enzo's Vertically Integrated Structure

    19 ECONOMIC BENEFITS OF ENZO’S VERTICALLY INTEGRATED STRUCTURE Average Gross Margin of Clinical Services Companies (1) ~30% Potential MDx Savings: Cumulative Royalty Relief Enzo owns all of its IP Intellectual property generation already paid for Lower Cost of Goods Enzo’s cumulative technological c

  21. Slide 21: Vertical Integration Eliminates Cost Redundancies

    20 ENZO’S VERTICAL INTEGRATION ELIMINATES COST REDUNDANCIES THE CURRENT LAYERED MARKET STRUCTURE ADDS MATERIAL COSTS Intellectual Property Biotech Innovation, Technology, and Test Platforms MDx Develop, Validate, and Manufacture Products Product Distribution, Sales, and Marketing Clinical Services $

  22. Slide 22: Enzo's Solution: Vertical Integration

    21 ENZO’S SOLUTION: VERTICAL INTEGRATION From Concept to Commercialization Innovation & IP Technology Platform Manufacturing Technology Validation Products & Services Biotech Molecular Diagnostics Clinical Services Products Services Via License BIOTECH, MD x, AND CLINICAL SERVICES COMPANIES IN TODAY

  23. Slide 23: Vertical Integration (continued)

    22 ENZO’S SOLUTION: VERTICAL INTEGRATION ( continued ) Commercial Optimization Very Difficult to Reproduce BIOTECH ▪ Market - Focused Innovation ▪ Technology Development ▪ Platform Development ▪ Intellectual Property MD x PRODUCTS ▪ Product Development ▪ Manufacturing ▪ Regulatory Validation ▪ Distr

  24. Slide 24: Biotech Contribution

    23 BIOTECH CONTRIBUTION Enzo’s platforms and technologies are the result of its development engine These lead to products that are: Cost - effective High - performance Easily adaptable Enzo’s Intellectual Property Assets Generate Returns that Serve as the Company’s Foundation

  25. Slide 25: Efficient Translation of Biotech Capabilities to Platforms

    24 EFFICIENT TRANSLATION OF BIOTECH CAPABILITIES TO PLATFORMS x Non - radioactive labeling and detection of nucleic acids x Amplification and quantification of nucleic acids x Proprietary dyes, bleachers, quenchers, and blockers x Enhanced detection of target via poly enzyme compounds x Homogenous a

  26. Slide 26: Example: AmpiProbe Platform

    25 EXAMPLE: AMPIPROBE PLATFORM LEADS TO PRODUCTS THAT WE BELIEVE AR E 30% - 50% THE COST OF REAL - TIME AMPLIFICATION DETECTION Less Sample x Allows paneling/reduced reaction volume/lower prep costs Multiplex Capability x Able to run up to 30 assays simultaneously Enhanced Sensitivity x Compared to

  27. Slide 27: Example: FlowScript Platform

    26 EXAMPLE: FLOWSCRIPT PLATFORM – FROM CONCEPT TO APPROVED ASSAY IN LESS THAN TWO YEARS Multiplex Capability x Simultaneous examinations of each cell in a sample Higher Efficiency x Designed to reduce hands - on time Consistent x Elimination of steps that can cause fluctuation in results Flexible, A

  28. Slide 28: Commercially Focused MDx Development

    27 COMMERCIALLY FOCUSED MD x DEVELOPMENT Large, well - developed markets – no missionary marketing efforts required C ost - effective, high - performing, and adaptable, Enzo’s products poised to penetrate the market Current MDx market pressures help create the need for these products Enzo’s self - d

  29. Slide 29: Example: AmpiProbe HCV

    28 EXAMPLE: AMPIPROBE™ HCV Platform formatted for both multiplexing (1) and paneling (2) This increases number of tests that can be run on a single specimen Reduces cost per test Reduces need for patients to provide additional specimens Can be run on virtually all commonly available open system Beca

  30. Slide 30: Example: FlowScript HPV E6/E7

    29 EXAMPLE: FLOWSCRIPT™ HPV E6/E7 FLOWSCRIPT™ PLATFORM DEVELOPED FROM IN - HOUSE TECHNOLOGIES Expansion of Enzo’s women’s health related products and services Measures activity of genes that may indicate progression toward cervical cancer Platform formatted for use with commonly available open lab i

  31. Slide 31: Enzo Has a Robust MDx Pipeline

    30 ENZO HAS A ROBUST MD x PIPELINE Product / Test Description Expected Availability Platform Opportunity (1) HPV E6/E7 Detection Available FLOWSCRIPT™ GENE EXPRESSION $200mm+ product $500mm service HCV Viral Load Available AMPIPROBE™ REAL - TIME AMPLIFICATION AND DETECTION $300mm product $450mm serv

  32. Slide 32: Translational Capability and Rapid Clinical Assay Validation

    31 Translational Capability x Bridge between product development from MDx platforms and service and product validation x Enzo rapidly adapts its development efforts to the clinical services market through constant feedback Rapid Clinical Assay Validation (Clinical Trials) x New York State regulation

  33. Slide 33: Clinical Services

    32 CLINICAL SERVICES x Technical Expertise x Accreditation x Logistics x IT – Lab x IT – Clients - Integrated into customers’ operations x Financial Services x Payor Relations – In - network with most major payors x Reputation for Excellence x Marketing and Sales Enzo H as Built a C linical Service

  34. Slide 34: National and Global Reach

    33 NATIONAL AND GLOBAL REACH NEW YORK STATE LICENSURE ALLOWS FOR A NATIONAL REACH , WHILE ENZO ACCREDITATIONS AND GLOBAL FOOTPRINT ALLOW FOR WORLDWIDE REACH Hawaii Alaska Continued expansion of national and worldwide sales and marketing presence Enzo’s strategy provides optionality to the market Pro

  35. Slide 35: Close Alignment with Payors

    34 CLOSE ALIGNMENT WITH PAYORS Private payors (insurance companies) increasingly control the practice of medicine and influence the specimen flow to service providers Enzo is currently in - network with most major payors We are well positioned to become the “ first - choice ” service provider to pay

  36. Slide 36: Summary

    35 SUMMARY The Company evaluated multiple internally generated technologies and platforms and selected those to further advance based on the development of: Products that could be sold at 30% - 50% less than the current market Products that could perform at or superior to market leaders’ products Me

  37. Slide 37: Summary (continued)

    36 SUMMARY ( continued ) To build the infrastructure we have developed would take hundreds of millions of dollars and many years – and there would be no guarantee that such an entity could amass the innovation, intellectual property, and structural efficiencies that would allow it to address the mar

  38. Slide 38: Financial Overview

    Enzo Financial Overview ae

  39. Slide 39: Recent Results

    38 RECENT RESULTS $93.7 $95.9 $97.6 $90.0 $92.0 $94.0 $96.0 $98.0 FY2013 FY2014 FY2015 Total Revenue ($ in millions) 6 - Month Total Shareholder Return (1) Sources: Company Filings, CapitalIQ (1) As of November 23, 2015 90.12% (1.8%) -20% 0% 20% 40% 60% 80% 100% Enzo Biochem Inc. Russell 3000 Index

  40. Slide 40: Recent Results (continued)

    0 100 200 300 400 500 600 700 800 900 1,000 $2.00 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 Volume (Thousands) Stock Price October 29, 2015: Enzo announces it has demonstrated new thresholds of sensitivity and breadth for its assay for the measurement of Hepatitis C virus (HCV) viral load November 17, 201

  41. Slide 41: Market Just Starting to Recognize Enzo's Potential

    -40% -20% 0% 20% 40% 60% 80% 100% Enzo Biochem Inc. Selected Lab Companies Selected Life Science Companies All Peers 40 MARKET JUST STARTING TO RECOGNIZE ENZO’S POTENTIAL 6 - Month Total Shareholder Return (1) Note: Selected Lab Companies: GHDX, NEO, SQNM, SHL, NTRA and VCYT. Note: Selected Life Sci

  42. Slide 42: Focus on Improving Efficiencies

    6.1% 4.2% 3.3% 3.4% 0% 1% 2% 3% 4% 5% 6% 7% FY 2012 FY 2013 FY 2014 FY 2015 46.5% 46.6% 43.6% 42.1% 39% 40% 41% 42% 43% 44% 45% 46% 47% FY 2012 FY 2013 FY 2014 FY 2015 41 FOCUS ON IMPROVING EFFICIENCIES SG&A Margin Improvement R&D to Sales Proven C ommitment to Control Costs Source: Company filings

  43. Slide 43: Enzo Clinical Services: Growth and Operating Leverage

    42 ENZO CLINICAL SERVICES: GROWTH AND OPERATING LEVERAGE Enzo Clinical Services Revenue Growth Enzo Clinical Services Gross Margins 31.6% 33.6% 37.6% 28% 29% 30% 31% 32% 33% 34% 35% 36% 37% 38% 39% FY 2013 FY 2014 FY 2015 $55.9 $58.7 $63.4 $50 $55 $60 $65 FY 2013 FY 2014 FY 2015 Enzo’s Strategy Is D

  44. Slide 44: Extremely Efficient R&D Investment

    $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Genomic Health Inc. Sequenom Inc. Natera, Inc. Veracyte, Inc. Enzo Labs and Sciences R&D Spend 5 yr 10 yr Sales TEV $273 $406 281 $762 181 315 137 261 63 63 189 392 43 43 48 157 16 (1) 40 (1) 98 189 43 E

  45. Slide 45: Appendices

    Enzo Appendices

  46. Slide 46: Appendix: IP Assets

    Enzo Appendix: IP Assets — as

  47. Slide 47: Return on IP Litigation Investment

    46 RETURN ON IP LITIGATION INVESTMENT 2011 - 15 Total (mm) Total Legal Fee Expense ($25.9) Legal Settlements, Net 27.6 IP Royalties 25.6 Net Gain 27.3 ($ in millions) THE FOUNDATION HAS BEEN LAID AND IS GENERATING RETURNS $25.9 $53.2 $- $10 $20 $30 $40 $50 $60 $70 $80 Amount Spent Amount Received So

  48. Slide 48: Appendix: Therapeutics

    Enzo Appendix: Therapeutics a

  49. Slide 49: Therapeutics' Product Pipeline

    48 THERAPEUTICS’ PRODUCT PIPELINE Product / Indication Discovery Preclinical Phase I Phase II Alequel™ for the treatment of Crohn’s disease Optiquel™ for the treatment of Autoimmune Uveitis The Company Continually R eviews its Therapeutics Program Seeking to Maximize S hareholder V alue

  50. Slide 50: Appendix: Definitions

    Enzo Appendix: Definitions — a —

  51. Slide 51: Definitions

    50 DEFINITIONS Molecular Diagnostics (MDx): The application of molecular techniques to detect, diagnose, and monitor diseases, it can include the use of nucleic acid (DNA/RNA) technologies, as well as monoclonal antibodies and ELISA - based assays for the study of immunology (1) Immunohistochemistry

  52. Slide 52: Appendix: Management Biographies

    Appendix: Management Biographies 51

  53. Slide 53: Management Biographies

    52 ELAZAR RABBANI, Ph . D . is an Enzo Biochem founder and has served as the Company’s Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25 , 2009 . Dr . Rabbani has authored numerous scientific publications in the field of molecular biology,

Enzo Biochem — Investor Presentation (November 2015) on 6ix